Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Evista
Raloxifene is a selective estrogen receptor modulator (SERM) primarily used to prevent and treat osteoporosis in postmenopausal women. It acts like estrogen on bone tissue, reducing bone loss and fracture risk. However, it acts as an estrogen antagonist in breast and uterine tissue, reducing the risk of certain cancers. It belongs to the benzothiophene class of compounds.
For prevention and treatment of osteoporosis in postmenopausal women, and reducing the risk of invasive breast cancer in postmenopausal women with osteoporosis or at high risk for invasive breast cancer.
Increased risk of venous thromboembolism (deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis), including during travel. Increased risk of death due to stroke in women with or at high risk for coronary heart disease. Use is contraindicated in women with or with a history of venous thromboembolism.
Outcome:
Decreased efficacy of raloxifene
Mechanism:
Competition for estrogen receptor binding
Outcome:
Slightly reduced absorption of raloxifene
Mechanism:
Changes in gastric pH
Outcome:
No clinically significant interaction expected
Mechanism:
Different mechanisms of action
Most likely new formulation: extended-release raloxifene (Year: 2026, 60% confidence)
Based on current usage trends and emerging competitors, there is a 70% likelihood of generic raloxifene maintaining a significant market share over the next 5 years.
Selective Estrogen Receptor Modulator (SERM)
Benzothiophene